questionsmedicales.fr
Acides nucléiques, nucléotides et nucléosides
Nucléotides
Ribonucléotides
Nucléotides uridyliques
Uridine diphosphate
Uridine diphosphate : Questions médicales fréquentes
Termes MeSH sélectionnés :
Programmed Cell Death 1 Receptor
Diagnostic
5
Carence en nucléotides
Tests biochimiques
Tests enzymatiques
Chromatographie
Fatigue
Troubles neurologiques
Marqueurs biologiques
Enzymes
Symptômes
5
Fatigue
Troubles cognitifs
Système nerveux
Troubles neurologiques
Douleurs musculaires
Métabolisme énergétique
Troubles de l'humeur
Carence en nucléotides
Anomalies cutanées
Carence en nucléotides
Prévention
5
Prévention
Alimentation équilibrée
Suppléments
Régime alimentaire
Groupes à risque
Troubles métaboliques
Habitudes de vie
Exercice
Conseils nutritionnels
Nutritionniste
Traitements
5
Suppléments
Modifications alimentaires
Thérapies alternatives
Nutrition
Alimentation
Acides nucléiques
Traitements spécifiques
Troubles métaboliques
Complications
5
Complications neurologiques
Complications métaboliques
Développement cognitif
Enfants
Maladies chroniques
Carence en nucléotides
Maladies héréditaires
Métabolisme
Troubles immunitaires
Infections
Facteurs de risque
5
Facteurs de risque
Régimes alimentaires
Âge
Carence en nucléotides
Maladies génétiques
Synthèse
Habitudes alimentaires
Carence en nucléotides
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Uridine diphosphate : Questions médicales les plus fréquentes",
"headline": "Uridine diphosphate : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Uridine diphosphate : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-07-22",
"dateModified": "2025-04-18",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Uridine diphosphate"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Nucléotides uridyliques",
"url": "https://questionsmedicales.fr/mesh/D014500",
"about": {
"@type": "MedicalCondition",
"name": "Nucléotides uridyliques",
"code": {
"@type": "MedicalCode",
"code": "D014500",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D13.695.827.919"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Uridine diphosphate ose",
"alternateName": "Uridine Diphosphate Sugars",
"url": "https://questionsmedicales.fr/mesh/D014539",
"about": {
"@type": "MedicalCondition",
"name": "Uridine diphosphate ose",
"code": {
"@type": "MedicalCode",
"code": "D014539",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D13.695.827.919.600.677"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Uridine diphosphate N-acétylgalactosamine",
"alternateName": "Uridine Diphosphate N-Acetylgalactosamine",
"url": "https://questionsmedicales.fr/mesh/D014536",
"about": {
"@type": "MedicalCondition",
"name": "Uridine diphosphate N-acétylgalactosamine",
"code": {
"@type": "MedicalCode",
"code": "D014536",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D13.695.827.919.600.677.100"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Uridine diphosphate N-acétylglucosamine",
"alternateName": "Uridine Diphosphate N-Acetylglucosamine",
"url": "https://questionsmedicales.fr/mesh/D014537",
"about": {
"@type": "MedicalCondition",
"name": "Uridine diphosphate N-acétylglucosamine",
"code": {
"@type": "MedicalCode",
"code": "D014537",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D13.695.827.919.600.677.120"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Acide uridine diphosphate N-acétylmuramique",
"alternateName": "Uridine Diphosphate N-Acetylmuramic Acid",
"url": "https://questionsmedicales.fr/mesh/D014538",
"about": {
"@type": "MedicalCondition",
"name": "Acide uridine diphosphate N-acétylmuramique",
"code": {
"@type": "MedicalCode",
"code": "D014538",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D13.695.827.919.600.677.150"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Uridine diphosphate galactose",
"alternateName": "Uridine Diphosphate Galactose",
"url": "https://questionsmedicales.fr/mesh/D014531",
"about": {
"@type": "MedicalCondition",
"name": "Uridine diphosphate galactose",
"code": {
"@type": "MedicalCode",
"code": "D014531",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D13.695.827.919.600.677.300"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Uridine diphosphate glucose",
"alternateName": "Uridine Diphosphate Glucose",
"url": "https://questionsmedicales.fr/mesh/D014532",
"about": {
"@type": "MedicalCondition",
"name": "Uridine diphosphate glucose",
"code": {
"@type": "MedicalCode",
"code": "D014532",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D13.695.827.919.600.677.350"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Acide uridine diphosphate glucuronique",
"alternateName": "Uridine Diphosphate Glucuronic Acid",
"url": "https://questionsmedicales.fr/mesh/D014535",
"about": {
"@type": "MedicalCondition",
"name": "Acide uridine diphosphate glucuronique",
"code": {
"@type": "MedicalCode",
"code": "D014535",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D13.695.827.919.600.677.375"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Uridine diphosphate xylose",
"alternateName": "Uridine Diphosphate Xylose",
"url": "https://questionsmedicales.fr/mesh/D014540",
"about": {
"@type": "MedicalCondition",
"name": "Uridine diphosphate xylose",
"code": {
"@type": "MedicalCode",
"code": "D014540",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D13.695.827.919.600.677.800"
}
}
}
]
}
],
"about": {
"@type": "MedicalCondition",
"name": "Uridine diphosphate",
"alternateName": "Uridine Diphosphate",
"code": {
"@type": "MedicalCode",
"code": "D014530",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Takayuki Matsumoto",
"url": "https://questionsmedicales.fr/author/Takayuki%20Matsumoto",
"affiliation": {
"@type": "Organization",
"name": "Department of Physiology and Morphology, Institute of Medicinal Chemistry, Hoshi University, Shinagawa-ku, Tokyo 142-8501, Japan. Electronic address: t-matsu@hoshi.ac.jp."
}
},
{
"@type": "Person",
"name": "Kumiko Taguchi",
"url": "https://questionsmedicales.fr/author/Kumiko%20Taguchi",
"affiliation": {
"@type": "Organization",
"name": "Department of Physiology and Morphology, Institute of Medicinal Chemistry, Hoshi University, Shinagawa-ku, Tokyo 142-8501, Japan."
}
},
{
"@type": "Person",
"name": "Tsuneo Kobayashi",
"url": "https://questionsmedicales.fr/author/Tsuneo%20Kobayashi",
"affiliation": {
"@type": "Organization",
"name": "Department of Physiology and Morphology, Institute of Medicinal Chemistry, Hoshi University, Shinagawa-ku, Tokyo 142-8501, Japan. Electronic address: tkoba@hoshi.ac.jp."
}
},
{
"@type": "Person",
"name": "Rafal Jonczyk",
"url": "https://questionsmedicales.fr/author/Rafal%20Jonczyk",
"affiliation": {
"@type": "Organization",
"name": "Biotechnology of Natural Products, Technische Universität München, 85354 Freising, Germany."
}
},
{
"@type": "Person",
"name": "Thomas Hoffmann",
"url": "https://questionsmedicales.fr/author/Thomas%20Hoffmann",
"affiliation": {
"@type": "Organization",
"name": "Biotechnology of Natural Products, Technische Universität München, 85354 Freising, Germany."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Progress in programmed cell death-1/programmed cell death-ligand 1 pathway inhibitors and binding mode analysis.",
"datePublished": "2022-08-10",
"url": "https://questionsmedicales.fr/article/35948846",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s11030-022-10509-2"
}
},
{
"@type": "ScholarlyArticle",
"name": "Programmed Cell Death-1/Programmed Cell Death-1 Ligand as Prognostic Markers of Coronavirus Disease 2019 Severity.",
"datePublished": "2022-06-20",
"url": "https://questionsmedicales.fr/article/35741107",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/cells11121978"
}
},
{
"@type": "ScholarlyArticle",
"name": "Identification of a novel cord blood NK cell subpopulation expressing functional programmed death receptor-1.",
"datePublished": "2023-06-22",
"url": "https://questionsmedicales.fr/article/37441071",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3389/fimmu.2023.1183215"
}
},
{
"@type": "ScholarlyArticle",
"name": "Biphenyl Ether Analogs Containing Pomalidomide as Small-Molecule Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction.",
"datePublished": "2022-05-27",
"url": "https://questionsmedicales.fr/article/35684392",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/molecules27113454"
}
},
{
"@type": "ScholarlyArticle",
"name": "Safety and Efficacy of Programmed Cell Death 1 and Programmed Death Ligand-1 Inhibitors in the Treatment of Cancer: An Overview of Systematic Reviews.",
"datePublished": "2022-07-13",
"url": "https://questionsmedicales.fr/article/35911744",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3389/fimmu.2022.953761"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Acides nucléiques, nucléotides et nucléosides",
"item": "https://questionsmedicales.fr/mesh/D009706"
},
{
"@type": "ListItem",
"position": 3,
"name": "Nucléotides",
"item": "https://questionsmedicales.fr/mesh/D009711"
},
{
"@type": "ListItem",
"position": 4,
"name": "Ribonucléotides",
"item": "https://questionsmedicales.fr/mesh/D012265"
},
{
"@type": "ListItem",
"position": 5,
"name": "Nucléotides uridyliques",
"item": "https://questionsmedicales.fr/mesh/D014500"
},
{
"@type": "ListItem",
"position": 6,
"name": "Uridine diphosphate",
"item": "https://questionsmedicales.fr/mesh/D014530"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Uridine diphosphate - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Uridine diphosphate",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-05",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Uridine diphosphate",
"description": "Comment diagnostiquer une carence en UDP ?\nQuels tests sont utilisés pour évaluer l'UDP ?\nL'UDP peut-il être mesuré dans le sang ?\nQuels symptômes indiquent un problème d'UDP ?\nY a-t-il des marqueurs spécifiques pour l'UDP ?",
"url": "https://questionsmedicales.fr/mesh/D014530?mesh_terms=Programmed+Cell+Death+1+Receptor#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Uridine diphosphate",
"description": "Quels sont les symptômes d'une carence en UDP ?\nL'UDP affecte-t-il le système nerveux ?\nDes douleurs musculaires peuvent-elles être liées à l'UDP ?\nL'UDP influence-t-il l'humeur ?\nY a-t-il des signes cutanés associés à l'UDP ?",
"url": "https://questionsmedicales.fr/mesh/D014530?mesh_terms=Programmed+Cell+Death+1+Receptor#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Uridine diphosphate",
"description": "Comment prévenir une carence en UDP ?\nLes suppléments sont-ils nécessaires pour l'UDP ?\nY a-t-il des groupes à risque pour l'UDP ?\nLes habitudes de vie influencent-elles l'UDP ?\nDes conseils nutritionnels existent-ils pour l'UDP ?",
"url": "https://questionsmedicales.fr/mesh/D014530?mesh_terms=Programmed+Cell+Death+1+Receptor#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Uridine diphosphate",
"description": "Comment traiter une carence en UDP ?\nLes médicaments peuvent-ils aider à l'UDP ?\nY a-t-il des thérapies alternatives pour l'UDP ?\nLes changements alimentaires sont-ils efficaces ?\nDes traitements spécifiques existent-ils pour l'UDP ?",
"url": "https://questionsmedicales.fr/mesh/D014530?mesh_terms=Programmed+Cell+Death+1+Receptor#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Uridine diphosphate",
"description": "Quelles complications peuvent survenir avec une carence en UDP ?\nL'UDP peut-il affecter le développement ?\nDes maladies chroniques sont-elles liées à l'UDP ?\nL'UDP est-il impliqué dans des maladies héréditaires ?\nDes troubles immunitaires peuvent-ils être liés à l'UDP ?",
"url": "https://questionsmedicales.fr/mesh/D014530?mesh_terms=Programmed+Cell+Death+1+Receptor#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Uridine diphosphate",
"description": "Quels sont les facteurs de risque pour l'UDP ?\nL'âge influence-t-il les niveaux d'UDP ?\nLe stress peut-il affecter l'UDP ?\nLes maladies génétiques influencent-elles l'UDP ?\nLes habitudes alimentaires jouent-elles un rôle ?",
"url": "https://questionsmedicales.fr/mesh/D014530?mesh_terms=Programmed+Cell+Death+1+Receptor#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une carence en UDP ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests biochimiques mesurant les niveaux d'UDP dans les cellules peuvent être effectués."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer l'UDP ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests enzymatiques et chromatographiques sont couramment utilisés pour évaluer l'UDP."
}
},
{
"@type": "Question",
"name": "L'UDP peut-il être mesuré dans le sang ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'UDP est généralement mesuré dans les tissus plutôt que dans le sang en raison de sa faible concentration."
}
},
{
"@type": "Question",
"name": "Quels symptômes indiquent un problème d'UDP ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes comme la fatigue, des troubles neurologiques ou des anomalies métaboliques peuvent survenir."
}
},
{
"@type": "Question",
"name": "Y a-t-il des marqueurs spécifiques pour l'UDP ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'existe pas de marqueurs spécifiques, mais des niveaux d'enzymes peuvent indiquer des anomalies."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes d'une carence en UDP ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent fatigue, faiblesse musculaire et troubles cognitifs."
}
},
{
"@type": "Question",
"name": "L'UDP affecte-t-il le système nerveux ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une carence en UDP peut entraîner des troubles neurologiques et cognitifs."
}
},
{
"@type": "Question",
"name": "Des douleurs musculaires peuvent-elles être liées à l'UDP ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des douleurs musculaires peuvent survenir en raison d'un métabolisme énergétique altéré."
}
},
{
"@type": "Question",
"name": "L'UDP influence-t-il l'humeur ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une carence en UDP peut affecter l'humeur et entraîner des troubles de l'humeur."
}
},
{
"@type": "Question",
"name": "Y a-t-il des signes cutanés associés à l'UDP ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des anomalies cutanées peuvent apparaître, mais elles sont moins fréquentes."
}
},
{
"@type": "Question",
"name": "Comment prévenir une carence en UDP ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation équilibrée riche en acides nucléiques peut aider à prévenir une carence."
}
},
{
"@type": "Question",
"name": "Les suppléments sont-ils nécessaires pour l'UDP ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les suppléments peuvent être bénéfiques, surtout en cas de régime alimentaire pauvre."
}
},
{
"@type": "Question",
"name": "Y a-t-il des groupes à risque pour l'UDP ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les personnes ayant des troubles métaboliques ou des régimes restrictifs sont à risque."
}
},
{
"@type": "Question",
"name": "Les habitudes de vie influencent-elles l'UDP ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des habitudes de vie saines, comme l'exercice, peuvent soutenir le métabolisme de l'UDP."
}
},
{
"@type": "Question",
"name": "Des conseils nutritionnels existent-ils pour l'UDP ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, consulter un nutritionniste peut aider à élaborer un plan alimentaire adapté."
}
},
{
"@type": "Question",
"name": "Comment traiter une carence en UDP ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement peut inclure des suppléments d'uridine et des modifications alimentaires."
}
},
{
"@type": "Question",
"name": "Les médicaments peuvent-ils aider à l'UDP ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certains médicaments peuvent améliorer le métabolisme de l'UDP, mais nécessitent une prescription."
}
},
{
"@type": "Question",
"name": "Y a-t-il des thérapies alternatives pour l'UDP ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des thérapies comme la nutrition ciblée peuvent être bénéfiques, mais nécessitent des études."
}
},
{
"@type": "Question",
"name": "Les changements alimentaires sont-ils efficaces ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une alimentation riche en acides nucléiques peut aider à augmenter les niveaux d'UDP."
}
},
{
"@type": "Question",
"name": "Des traitements spécifiques existent-ils pour l'UDP ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Actuellement, il n'existe pas de traitements spécifiques approuvés pour les troubles liés à l'UDP."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec une carence en UDP ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications neurologiques et métaboliques peuvent survenir si non traitées."
}
},
{
"@type": "Question",
"name": "L'UDP peut-il affecter le développement ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une carence en UDP peut nuire au développement cognitif et physique chez les enfants."
}
},
{
"@type": "Question",
"name": "Des maladies chroniques sont-elles liées à l'UDP ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines maladies métaboliques chroniques peuvent être exacerbées par une carence en UDP."
}
},
{
"@type": "Question",
"name": "L'UDP est-il impliqué dans des maladies héréditaires ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des troubles héréditaires du métabolisme peuvent affecter les niveaux d'UDP."
}
},
{
"@type": "Question",
"name": "Des troubles immunitaires peuvent-ils être liés à l'UDP ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une carence en UDP peut affaiblir le système immunitaire, augmentant le risque d'infections."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque pour l'UDP ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les régimes alimentaires pauvres, les maladies métaboliques et le stress sont des facteurs de risque."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il les niveaux d'UDP ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les niveaux d'UDP peuvent diminuer avec l'âge, augmentant le risque de carence."
}
},
{
"@type": "Question",
"name": "Le stress peut-il affecter l'UDP ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress chronique peut perturber le métabolisme de l'UDP et entraîner des carences."
}
},
{
"@type": "Question",
"name": "Les maladies génétiques influencent-elles l'UDP ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines maladies génétiques peuvent affecter la synthèse et l'utilisation de l'UDP."
}
},
{
"@type": "Question",
"name": "Les habitudes alimentaires jouent-elles un rôle ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une alimentation déséquilibrée peut augmenter le risque de carence en UDP."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 18/04/2025
Contenu vérifié selon les dernières recommandations médicales
3 publications dans cette catégorie
Affiliations :
Department of Physiology and Morphology, Institute of Medicinal Chemistry, Hoshi University, Shinagawa-ku, Tokyo 142-8501, Japan. Electronic address: t-matsu@hoshi.ac.jp.
Publications dans "Uridine diphosphate" :
3 publications dans cette catégorie
Affiliations :
Department of Physiology and Morphology, Institute of Medicinal Chemistry, Hoshi University, Shinagawa-ku, Tokyo 142-8501, Japan.
Publications dans "Uridine diphosphate" :
3 publications dans cette catégorie
Affiliations :
Department of Physiology and Morphology, Institute of Medicinal Chemistry, Hoshi University, Shinagawa-ku, Tokyo 142-8501, Japan. Electronic address: tkoba@hoshi.ac.jp.
Publications dans "Uridine diphosphate" :
2 publications dans cette catégorie
Affiliations :
Biotechnology of Natural Products, Technische Universität München, 85354 Freising, Germany.
Publications dans "Uridine diphosphate" :
2 publications dans cette catégorie
Affiliations :
Biotechnology of Natural Products, Technische Universität München, 85354 Freising, Germany.
Publications dans "Uridine diphosphate" :
2 publications dans cette catégorie
Affiliations :
Biotechnology of Natural Products, Technische Universität München, 85354 Freising, Germany wilfried.schwab@tum.de.
Publications dans "Uridine diphosphate" :
2 publications dans cette catégorie
Affiliations :
Department of Pediatrics, The First Affiliated Hospital of Guangxi Medical University, No. 6 Shuangyong Road, Nanning 530021, Guangxi, China.
Publications dans "Uridine diphosphate" :
2 publications dans cette catégorie
Affiliations :
Key Laboratory for Molecular Enzymology and Engineering of Ministry of Education, School of Life Science, Jilin University, Changchun 130021, China.
Publications dans "Uridine diphosphate" :
2 publications dans cette catégorie
Affiliations :
Key Laboratory for Molecular Enzymology and Engineering of Ministry of Education, School of Life Science, Jilin University, Changchun 130021, China.
Publications dans "Uridine diphosphate" :
2 publications dans cette catégorie
Affiliations :
Key Laboratory for Molecular Enzymology and Engineering of Ministry of Education, School of Life Science, Jilin University, Changchun 130021, China.
Publications dans "Uridine diphosphate" :
2 publications dans cette catégorie
Affiliations :
The Key Laboratory of Natural Medicine and Immuno-Engineering, Henan University, Kaifeng 475004, China. Electronic address: zhaoyuan@henu.edu.cn.
Publications dans "Uridine diphosphate" :
2 publications dans cette catégorie
Affiliations :
Agronomy College, Sichuan Agricultural University, Chengdu 611130, China.
Publications dans "Uridine diphosphate" :
2 publications dans cette catégorie
Affiliations :
Faculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, British Columbia, Canada.
Publications dans "Uridine diphosphate" :
2 publications dans cette catégorie
Affiliations :
Faculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, British Columbia, Canada.
Publications dans "Uridine diphosphate" :
2 publications dans cette catégorie
Affiliations :
Department of Physiology and Morphology, Institute of Medicinal Chemistry, Hoshi University, Shinagawa-ku, Tokyo, 142-8501, Japan.
Publications dans "Uridine diphosphate" :
2 publications dans cette catégorie
Affiliations :
Department of Physiology and Morphology, Institute of Medicinal Chemistry, Hoshi University, Shinagawa-ku, Tokyo, 142-8501, Japan.
Publications dans "Uridine diphosphate" :
2 publications dans cette catégorie
Affiliations :
Department of Physiology and Morphology, Institute of Medicinal Chemistry, Hoshi University, Shinagawa-ku, Tokyo, 142-8501, Japan.
Publications dans "Uridine diphosphate" :
2 publications dans cette catégorie
Affiliations :
State Key Laboratory Breeding Base of Dao-di Herbs, National Resource Center for Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, China.
School of Pharmacy, Henan University of Chinese Medicine, Zhengzhou, China.
Publications dans "Uridine diphosphate" :
2 publications dans cette catégorie
Affiliations :
State Key Laboratory Breeding Base of Dao-di Herbs, National Resource Center for Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, China.
Department of Chemistry, The Scripps Research Institute, Jupiter, FL, United States.
Publications dans "Uridine diphosphate" :
2 publications dans cette catégorie
Affiliations :
State Key Laboratory Breeding Base of Dao-di Herbs, National Resource Center for Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, China.
Publications dans "Uridine diphosphate" :
Programmed cell death protein 1 (PD-1)/programmed cell death protein ligand 1 (PD-L1) plays an important role in negative regulating immunity. The search for effective PD-1/PD-L1 inhibitors has been a...
Current research proves that immune dysregulation is a common feature of coronavirus disease 2019 (COVID-19), and immune exhaustion is associated with increased disease mortality. Immune checkpoint mo...
Natural Killer cells (NKs) represent the innate counterpart of TCRαβ lymphocytes and are characterized by a high anti-tumor and an anti-viral cytotoxic activity. Recently, it has been demonstrated tha...
In this study, we analyzed the expression and function of PD-1 on Cord Blood derived NKs (CB-NKs) on a large cohort of newborns through multiparametric cytofluorimetric analysis....
We identified PD-1 on CB-NKs in more than of half the newborns analyzed. PD-1 was present on CD56...
To our understanding, this study is the first to report PD-1 expression on CB derived NKs and its features in perinatal conditions. These data may prove important in selecting the most suitable CB der...
New biphenyl-based chimeric compounds containing pomalidomide were developed and evaluated for their activity to inhibit and degrade the programmed cell death-1/programmed cell death- ligand 1 (PD-1/P...
An influx of systematic reviews (SRs) of programmed cell death 1 (PD-1) and programmed death ligand-1 (PD-L1) checkpoint inhibitors in cancer treatment with or without meta-analysis and with different...
A comprehensive search of SRs, which included meta-analyses of PD-(L)1 inhibitors on cancer, was performed on eight databases with a cutoff date of 1 January 2022. Two authors independently identified...
A total of 172 SRs with meta-analysis met the inclusion criteria. The report quality of included SRs was quite good, with 128 (74.42%) SRs of high quality and 44 (25.58%) of moderate quality. The meth...
PD-(L)1 inhibitors appeared to be effective and safe for cancer treatment, except for gastrointestinal tumors; however, the quality of the evidence is not convincing. Future studies should improve met...
http://www.crd.york.ac.uk/prospero, identifier CRD42020194260....
Programmed death receptor 1 (PD-1) is an inhibitory receptor on T cells shown to restrain T-cell proliferation. PD-1 immune checkpoint blockade has emerged as a highly promising approach in cancer tre...
A series of novel compounds bearing a cyclopropyl linkage were designed, synthesized, and evaluated as programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) inhibitors. An optimized co...
Multiple clinical studies have indicated that the gut microbiota influences the effects of immune checkpoint blockade (ICB) therapy comprising PD-1/PD-L1 inhibitors, but the causal relationship is unc...
We used bidirectional two-sample Mendelian randomization with two different thresholds to explore the potential causal relationship between the microbiota and PD-1/PD-L1 and species-level microbiota G...
In the primary forward analysis, genus_Holdemanella showed a negative correlation with PD-1 [βIVW = -0.25; 95% CI (-0.43 to -0.07); P...
Checkpoint blockade of the immunoreceptor programmed cell death-1 (PD1) with its ligand-1 (PDL1) by monoclonal antibodies such as pembrolizumab provided compelling clinical results in various cancer t...
Preeclampsia is a pregnancy-specific disease which is characterized by abnormal placentation, endothelial dysfunction, systemic inflammation and disruption of the immune system. The goal of this study...